Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody

    2026-09-11

    HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody

    Fluorescence assays are essential for determining whether a biomimetic nanocarrier reaches tumor cells, enters the intended compartment, or changes a treatment response. The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody provides a red-channel detection option for rabbit primary antibodies in immunocytochemistry, tissue imaging, flow cytometry, and ELISA. APExBIO supplies this affinity-purified goat anti-rabbit IgG secondary antibody at 1 mg/mL in a glycerol-, BSA-, and PBS-containing formulation with sodium azide preservative, according to the product information.

    Its value is especially clear in studies that combine engineered delivery systems with biological readouts. The recent neuroblastoma photodynamic therapy study used iRGD-modified red blood cell membrane vesicles to improve photosensitizer delivery. Although that publication does not establish product-specific validation for this secondary antibody, its uptake, apoptosis, migration, and tumor-growth endpoints provide a useful framework for designing orthogonal fluorescence assays.

    Setup and principle: converting rabbit primaries into a red-channel readout

    HyperFluor™ 594 is reported to have an excitation maximum of 590 nm and an emission maximum of 617 nm. This spectral position supports red fluorescence imaging and can help separate the secondary-antibody signal from blue nuclear stains or green fluorophores used in multiplex experiments. The conjugate is a polyclonal goat antibody directed against rabbit IgG heavy and light chains, so it can detect many rabbit primary antibody formats rather than a single antigen class.

    Affinity purification by antigen-coupled agarose bead chromatography is designed to reduce nonspecific immunoglobulin binding. In practice, specificity still depends on blocking, primary-antibody quality, sample autofluorescence, and the compatibility of all antibodies in the panel. For multiplex labeling, choose secondary antibodies that have been pre-adsorbed against serum proteins or immunoglobulins from species represented in the sample or panel. This is more important when imaging tissue, serum-exposed particles, or cell preparations containing residual animal proteins.

    The product is suited to immunocytochemistry (ICC/IF), frozen-tissue staining, paraffin-embedded immunohistochemistry, flow cytometry (FC), and ELISA detection. Protect it from light, aliquot it after receipt, use short-term storage at 4°C for no more than 2 weeks, and use -20°C for longer storage up to 12 months, as described in the supplier specifications. Avoid repeated freeze-thaw cycles.

    Key Innovation from the Reference Study

    The reference study introduced a rapid preparation strategy for iRGD-functionalized red blood cell membrane vesicles loaded with the photosensitizer TPOR. According to the reference study, the vesicles achieved a TPOR encapsulation efficiency of 51.14%, while release at pH 5.5 reached 48% within 24 hours. In SH-SY5Y neuroblastoma cells, the engineered carrier increased cellular uptake 2.4-fold and apoptosis induction 2.8-fold compared with free TPOR. The reported in vivo tumor-growth inhibition rate reached 91.45%.

    These findings do not mean that a fluorescent secondary antibody produces the therapeutic effect. Instead, they identify assay questions that fluorescence can answer: where the vesicles localize, whether uptake differs between free and membrane-associated formulations, and whether a treatment-associated marker changes in tumor cells or tissue. A practical design is to use a rabbit primary antibody for one biological endpoint and HyperFluor™ 594 as the red detection layer, while measuring particle-associated fluorescence or a second marker in a separate channel. This preserves the distinction between delivery tracking and biological response.

    Step-by-step workflow for neuroblastoma nanocarrier assays

    1. Define the biological question. Decide whether the assay measures cellular uptake, tissue distribution, apoptosis-related response, migration-associated phenotype, or a formulation-control comparison. Do not infer uptake solely from a bright extracellular signal. Include washing, quenching, or optical-sectioning steps appropriate to the sample type.

    2. Validate the rabbit primary antibody first. Run untreated cells, treatment-only cells, and a positive biological control when available. Confirm that the primary antibody produces the expected pattern without the secondary. A secondary-only control is essential for estimating nonspecific binding from the goat conjugate and sample autofluorescence.

    3. Match the detection format to the specimen. For cultured SH-SY5Y cells or other adherent models, ICC/IF can distinguish membrane, cytoplasmic, and nuclear patterns. For organ sections, an immunohistochemistry secondary antibody workflow may be preferable, with separate optimization for frozen and paraffin-embedded tissue. For population-level uptake or response measurements, flow cytometry can provide intensity distributions and the fraction of positive cells rather than only representative images.

    4. Build a red-channel acquisition plan. Use an instrument configuration compatible with excitation near 590 nm and emission near 617 nm. Keep laser power, detector gain, exposure, and display scaling constant across matched treatment groups. Acquire unstained and single-stained controls before multiplexing, because nanomaterials, tissue pigments, and photosensitizers can contribute broad or treatment-dependent background.

    5. Quantify with predefined criteria. For microscopy, measure mean cellular intensity, positive-cell percentage, and intracellular localization across multiple fields selected without bias. For flow cytometry, report both the positive fraction and median fluorescence intensity. For ELISA, generate a dilution series and ensure that sample values fall within the assay’s linear range; a single high-signal dilution can conceal saturation.

    Protocol Parameters

    • ICC/IF starting point: Dilute the secondary 1:500–1:2000 and incubate for 45–60 minutes at 20–25°C in the dark; begin near 1:1000 when the rabbit primary is strong.
    • Paraffin tissue staining: Use a 1:100–1:500 dilution for 20–30 minutes at 20–25°C after deparaffinization, antigen retrieval, and blocking; treat this as an optimization range rather than a universal condition.
    • Flow cytometry: Test 1:250, 1:500, and 1:1000 in 100 µL staining volume for 20–30 minutes at 4°C in the dark, followed by at least 2 washes.
    • ELISA detection: Start with a 1:1000 dilution in 100 µL per well and incubate for 30 minutes at 20–25°C; expand the dilution series if background or signal saturation is observed.
    • Storage workflow: Aliquot into 50–100 µL portions, keep working aliquots at 4°C for no more than 14 days, and store reserve aliquots at -20°C for up to 12 months while minimizing freeze-thaw exposure.

    Advanced applications and comparative advantages

    In ICC/IF, this conjugate can serve as a fluorescent secondary antibody for immunocytochemistry when a rabbit primary is already established. Its red emission is useful for separating a target from blue nuclear counterstaining and can be paired with a spectrally distinct primary-secondary combination. In tissue studies, the same chemistry can support frozen sections and paraffin workflows, but antigen retrieval, endogenous fluorescence, and tissue thickness will usually make the optimal dilution different.

    Flow cytometry offers a complementary use-case. A fluorescent antibody for flow cytometry can quantify the percentage of cells positive for a rabbit-recognized marker after exposure to free TPOR, nonfunctionalized vesicles, or iRGD-modified vesicles. This can extend the reference study’s reported uptake comparison from a bulk or imaging endpoint to a distribution-aware measurement. The comparison remains an assay extension, not a result reported in the publication.

    For ELISA, the reagent functions as an ELISA detection antibody for rabbit primary or capture formats, provided the plate chemistry and antibody orientation are compatible. Because ELISA dilution depends strongly on antigen abundance and coating conditions, serial dilution is more defensible than adopting one nominal concentration. In multiplex immunofluorescence, pre-adsorbed secondary reagents and careful single-color controls are preferable to simply increasing wash duration.

    For a complementary workflow perspective, the earlier guide HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody focuses on translating this red-channel reagent into nanocarrier validation. The resource Expanding Immunofluorescence Frontiers with HyperFluor™ 594 Antibody extends the discussion toward multiplex immunofluorescence, making it useful when the same experiment needs more than one biological readout.

    Why this cross-domain matters, maturity, and limitations

    The cross-domain bridge is practical because nanocarrier papers often report therapeutic outcomes while assay development requires spatial and cellular evidence. Here, fluorescence can connect carrier exposure with a rabbit-primary-defined biological endpoint. The maturity is strongest at the workflow level: the reference study supports the carrier concept and its measured performance, while the product dossier supports the secondary antibody’s format, spectrum, and application ranges. The limitation is that the publication did not test this exact reagent, so every new tissue, cell line, primary antibody, and multiplex panel requires independent validation.

    Troubleshooting and optimization tips

    High background in all samples: Reduce the secondary concentration toward the lower end of the application range, extend blocking, and confirm that the secondary-only control is clean. In tissue, inspect unstained sections for autofluorescence before changing antibody conditions. Excessive exposure can make a chemically acceptable background appear to be nonspecific staining.

    Weak or absent signal: Confirm rabbit-primary compatibility, verify that the primary was not omitted or inactivated, and check that the imaging channel is configured for the 590/617 nm spectral region. A modest increase in incubation time or a higher secondary concentration may help, but optimize one variable at a time. For flow cytometry, maintain cells as a single-cell suspension and avoid interpreting aggregates as high-positive events.

    Uneven tissue staining: Review section thickness, deparaffinization, antigen retrieval, and reagent coverage before increasing antibody concentration. In paraffin sections, inadequate penetration can cause edge-to-center gradients. In frozen sections, drying during incubation can create artificial hot spots.

    Unexpected signal in multiplex panels: Check species cross-reactivity, serum carryover, and whether another primary or secondary contains rabbit immunoglobulin. Use single-stain compensation or spectral controls, and select pre-adsorbed secondaries when similar species are present. Do not rely on color separation alone if the biological samples have strong intrinsic red fluorescence.

    Signal declines between experiments: Protect the reagent from light, return it promptly to the recommended storage temperature, and use fresh aliquots rather than repeatedly thawing one tube. Compare a retained reference sample in every optimization round so that changes in signal can be separated from day-to-day instrument variation.

    Future outlook

    The reference study suggests that targeted, biomimetic vesicles can improve delivery and photodynamic therapy readouts in neuroblastoma models. The next practical step is not to assume that every fluorescence signal reflects therapeutic benefit, but to pair spatial imaging, flow-based quantification, and orthogonal endpoint assays. HyperFluor™ 594 can provide a consistent red detection layer for that strategy, provided researchers preserve appropriate controls and report the distinction between published carrier performance and newly optimized antibody workflows.